W. P. Peters - Concepedia

Author

W. P. Peters

Duke Medical Center

Also Known As

W P Peters, W Peters, W. P. PETERS, W. P. Peters, W. Peters, W.P. PETERS, W.P. Peters, WP Peters, Willjam P. Peters

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Duke University Hospital Columbia University Harvard University Press

About

W. P. Peters is an author at Duke Medical Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	1.2K
2	Health Sciences	8	8	614
3	Natural Sciences	1	1	32
4	Allergy	1	1	73
5	Biomedical Engineering	1	1	26

W. P. Peters

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. W. P. Peters, Maureen Ross, James J. Vredenburgh, Journal of Clinical Oncology	1993	502
High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. W. P. Peters, E.J. Shpall, R B Jones, Journal of Clinical Oncology Metastatic Breast CancerBreast OncologyMedian DurationMedicinePharmacology	1988	384
High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. Joseph P. Eder, Karen H. Antman, W. P. Peters, Journal of Clinical Oncology Metastatic Breast CancerOncologyAgent ChemotherapyBreast OncologyBone Marrow Harvest	1986	130
High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. W. P. Peters, Joseph P. Eder, W. David Henner, Journal of Clinical Oncology Cell TherapyPharmacotherapyHigh-dose CombinationExcessive RenalRegenerative Medicine	1986	121
The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. W. P. Peters, Mark Ross, James J. Vredenburgh, PubMed	1994	75
Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. W. P. Peters, W. David Henner, L B Grochow, PubMed Solid TumorsImmunologyPathologyPharmacotherapyPharmacologic Effects	1987	73
Clinical and pharmacological phase I evaluation of Exherin™ (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours Antonella Perotti, Cristiana Sessa, Andrea Mancuso, Annals of Oncology N-cadherin-expressing Solid TumoursPharmacological PhaseMedicineSelective Anti-n-cadherin PeptidePathology	2009	72
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. Mary J. Laughlin, Dean McGaughey, James Crews, Journal of Clinical Oncology	1998	64
Prognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous Stem-Cell Support David A. Rizzieri, James J. Vredenburgh, Roy B. Jones, Journal of Clinical Oncology	1999	60
Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. Rebecca H. Buckley, Sherrie E. Schiff, R.I. Schiff, PubMed	1993	58

Page 1